Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
GAITHERSBURG, Md., Feb. 09, 2017 -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 23, 2017 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full twelve months of 2016, recent business developments, financial outlook for full year 2017, and revenue guidance for the first quarter of 2017.
This conference call can be accessed live by telephone or via webcast:
| Live Teleconference Information: |
| Dial in number: (855) 766-6521 |
| International dial in: (262) 912-6157 |
| Conference ID: 29688886 |
| Live Webcast Information: |
| Visit edge.media-server.com/m/p/qbs3g23i for the live webcast feed. |
A replay of the call can be accessed on Emergent’s website emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at emergentbiosolutions.com. Follow us @emergentbiosolu.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Tracey Schmitt Lintott Senior Vice President, Global Public Affairs 240-631-3281 [email protected]
